ClinicalTrials.gg
RecruitingNCT06954961Updated Mar 31, 2026

A Study to Evaluate D-0502 in Subjects With ER+ Her2- Locally Advanced or Metastatic Breast Cancer

A Phase 3 interventional study of D-0502 and Fulvestrant in Breast Cancer, sponsored by InventisBio Co., Ltd. Recruiting at 2 sites in China. Open to female participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-03-31.

Sponsored by InventisBio Co., Ltd · Phase 3, Interventional, and Treatment

From the registry’s dates

  • Registered 2 years 3 months after the study started (first participant enrolled Sep 2022, registered Dec 2024).
  • Started Sep 2022; still recruiting 4 years 2 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
640
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 1,928 studies in Breast Neoplasms with a site in China — 866 open to participants now, 1,064 under way, 210 of them phase 3. Breast Neoplasms · China.

Planned enrollment
167th of 1,519
640 · median 120
Started
2022
with 179 others
Phase 3
331 of 1,928
120 open now
Primary completion
2026-11
later than 499 of 1,063 live
Registered
1,460th of 1,928
by date

Among the 1,928 studies in Breast Neoplasms with a site in China, this one is the 167th largest by planned enrollment of the 1,519 interventional ones that give a count, is one of 180 that started in 2022, is one of 331 in phase 3, reaches primary completion later than 499 of the 1,063 other live ones, and was the 1,460th registered.

Breast Neoplasms

14,837 studies on the registry are indexed under Breast Neoplasms; 3,322 are open to participants now.

Browse Breast Neoplasms studies →

Open to participants now

866 of the 1,928 studies in Breast Neoplasms with a site in China are open now. Recruiting first, the newest first:

861 more — sign in →

All 866 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 2,400 Breast Neoplasms studies recruiting now, 1,572 (66%) set no upper age limit and 591 (25%) stop at 75 or younger; 103 take children under 18; 214 take healthy volunteers.

This study: 18 Years to 75 Years · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 1,928 studies in Breast Neoplasms with a site in China, or all of them as a file.
02

Study summary

This is a randomized, parallel-controlled, open-label, multicenter clinical study to assess the efficacy and safety of D-0502 in the treatment of subjects with ER-positive, HER2-negative locally advanced or metastatic breast cancer with fulvestrant injection as a control drug.

03

Conditions studied

  • Breast Cancer

Browse trials for

04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Subjects confirmed with ER-positive, -negative breast cancer;
  • Subjects with locally advanced (unresectable) or breast cancer who have disease recurrence during or after endocrine therapy, or whose disease has progressed after 1-2 lines of systemic endocrine therapy;
  • Presence of at least 1 that can be measured by CT or MRI based on V1.1 criteria; in the absence of measurable lesions, subjects with evaluable bone lesions [osteolytic or mixed (osteolytic + osteogenic) bone lesions] are also acceptable. Lesions that have been previously treated with radiotherapy or other local therapy can be regarded as measurable lesions only if there is disease progression as confirmed by imaging examination;
  • Expected survival time ≥ 12 weeks;

Exclusion criteria

Exclusion Criteria:

  • Subjects with unstable or symptomatic or progressive central nervous system (CNS) . Subjects with a history of who are clinically stable and have no CNS disease progression confirmed by brain MRI or CT (if MRI is not appropriate) can be enrolled (MRI or CT examination must be conducted at least 4 weeks after the last brain radiotherapy);
  • Subjects with locally advanced or metastatic breast cancer who have previously received more than 2 prior systemic chemotherapy;
  • Subjects are unsuitable for endocrine therapy judged by the investigator, including uncontrolled pleural effusion, ascites or pericardial effusion;
  • Subjects with concomitant medical conditions that the investigator believes may increase the risk of toxicity, such as serious cardiovascular, respiratory or neurological diseases;
  • Prior treatment with a selective estrogen receptor degrader (SERD)/selective estrogen receptor covalent antagonist (SERCA), such as fulvestrant, GDC-9545, AZD9833, SAR-439859, Zn -c5, LX-039, HS234, etc.;
  • Pregnant or lactating females;
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

HER2

HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.

In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
640 participants (estimated)

Study arms

  • Experimental
    D-0502

    Drug: D-0502

  • Active comparator
    Fulvestrant

    Drug: Fulvestrant

Interventions

  • DrugD-0502

    * Dosage form: Tablet * Administration route: Oral, once a day

  • * Dosage form: Injection * Administration route: Intramuscular injection, once a month, and another dose administered two weeks after the first dose

06

What researchers measure

Primary outcomes

  1. Progression free survival (PFS) assessed by Independent Review Committee (IRC)

    Time frame: From enrollment to the end of treatment, up to 2 years

Secondary outcomes

  1. Progression free survival (PFS) -assessed by investigators

    Time frame: From enrollment to the end of treatment, up to 2 years

  2. Objective response rate (ORR) -assessed by IRC and investigators

    Time frame: From enrollment to the end of treatment, up to 2 years

  3. Clinical benefit rate (CBR) -assessed by IRC and investigators

    Time frame: From enrollment to the end of treatment, up to 2 years

  4. Disease control rate (DCR)-assessed by IRC and investigators

    Time frame: From enrollment to the end of treatment, up to 2 years

  5. Clearance (Cl) of D-0502

    Time frame: on Cycle 1 Day 1, Cycle 1 Day 15, Cycle 2 Day 1 and Cycle 3 Day 1 (each cycle is 28 days)

  6. Overall Survival (OS)

    Time frame: From end of treatment to end of study, about 2 years

  7. Number of participants with adverse events/serious adverse events and abnormal laboratory test results

    Time frame: From enrollment to 30 days after last dose

  8. Volume of distribution (Vd) of D-0502

    Time frame: on Cycle 1 Day 1, Cycle 1 Day 15, Cycle 2 Day 1 and Cycle 3 Day 1 (each cycle is 28 days)

07

Study locations

2 of 2 sites recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Sep 2022 (actual). Primary completion is estimated for Nov 2026, 50 months after the start.

Of 272 industry-sponsored phase 3 interventional studies under Breast Neoplasms, half reached primary completion within 40 months of starting (the median), counting those still running; a quarter within 28 and three quarters within 63. This study's planned 50 months is above that.

Counting every sponsor, half of 600 studies reached it within 59 months; a quarter within 36 and three quarters within 96.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 20, 2024
First posted
May 2, 2025
StartActual
Sep 15, 2022
Primary completionEst.
Nov 30, 2026
CompletionEst.
Dec 31, 2028
Last update
Mar 31, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 31, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT06954961
Responsible party
Sponsor
First posted
May 2, 2025
Start date
Sep 15, 2022
Primary completion
Nov 30, 2026 (estimated)
Completion
Dec 31, 2028 (estimated)
Last update
Mar 31, 2026

Study contacts

Yuting Li
Contact
yuting.li@inventisbio.com
8615821378026
Binghe Xu, MD
principal investigator · Cancer Hospital
Qingyuan Zhang, MD
principal investigator · Harbin

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Taragarestrant

Start the discussion